Cargando…

Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes

Duodenal mucosal resurfacing (DMR) is a new endoscopic ablation technique aimed at improving glycemia and metabolic control in patients with type 2 diabetes mellitus (T2DM). DMR appears to improve insulin resistance, which is the root cause of T2DM, but its mechanism of action is largely unknown. Bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Meiring, Suzanne, Meessen, Emma C. E., van Baar, Annieke C. G., Holleman, Frits, Nieuwdorp, Max, Olde Damink, Steven W., Schaap, Frank G., Vaz, Fred M., Groen, Albert K., Soeters, Maarten R., Bergman, Jacques J. G. H. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Physiological Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858668/
https://www.ncbi.nlm.nih.gov/pubmed/34957857
http://dx.doi.org/10.1152/ajpendo.00337.2021
_version_ 1784654287813476352
author Meiring, Suzanne
Meessen, Emma C. E.
van Baar, Annieke C. G.
Holleman, Frits
Nieuwdorp, Max
Olde Damink, Steven W.
Schaap, Frank G.
Vaz, Fred M.
Groen, Albert K.
Soeters, Maarten R.
Bergman, Jacques J. G. H. M.
author_facet Meiring, Suzanne
Meessen, Emma C. E.
van Baar, Annieke C. G.
Holleman, Frits
Nieuwdorp, Max
Olde Damink, Steven W.
Schaap, Frank G.
Vaz, Fred M.
Groen, Albert K.
Soeters, Maarten R.
Bergman, Jacques J. G. H. M.
author_sort Meiring, Suzanne
collection PubMed
description Duodenal mucosal resurfacing (DMR) is a new endoscopic ablation technique aimed at improving glycemia and metabolic control in patients with type 2 diabetes mellitus (T2DM). DMR appears to improve insulin resistance, which is the root cause of T2DM, but its mechanism of action is largely unknown. Bile acids function as intestinal signaling molecules in glucose and energy metabolism via the activation of farnesoid X receptor and secondary signaling [e.g., via fibroblast growth factor 19 (FGF19)], and are linked to metabolic health. We investigated the effect of DMR and glucagon-like peptide-1 (GLP-1) on postprandial bile acid responses in 16 patients with insulin-dependent T2DM, using mixed meal tests performed at the baseline and 6 mo after the DMR procedure. The combination treatment allowed discontinuation of insulin treatment in 11/16 (69%) of patients while improving glycemic and metabolic health. We found increased postprandial unconjugated bile acid responses (all P < 0.05), an overall increased secondary bile acid response (P = 0.036) and a higher 12α-hydroxylated:non-12α-hydroxylated ratio (P < 0.001). Total bile acid concentrations were unaffected by the intervention. Postprandial FGF19 and 7-α-hydroxy-4-cholesten-3-one (C4) concentrations decreased postintervention (both P < 0.01). Our study demonstrates that DMR with GLP-1 modulates the postprandial bile acid response. The alterations in postprandial bile acid responses may be the result of changes in the microbiome, ileal bile acid uptake and improved insulin sensitivity. Controlled studies are needed to elucidate the mechanism linking the combination treatment to metabolic health and bile acids. NEW & NOTEWORTHY Glycemic and metabolic improvements are seen in patients with type 2 diabetes after replacing their insulin therapy with DMR and GLP-1. These changes are accompanied by changes in postprandial bile acid concentrations: increased unconjugated and secondary bile acids.
format Online
Article
Text
id pubmed-8858668
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Physiological Society
record_format MEDLINE/PubMed
spelling pubmed-88586682022-03-03 Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes Meiring, Suzanne Meessen, Emma C. E. van Baar, Annieke C. G. Holleman, Frits Nieuwdorp, Max Olde Damink, Steven W. Schaap, Frank G. Vaz, Fred M. Groen, Albert K. Soeters, Maarten R. Bergman, Jacques J. G. H. M. Am J Physiol Endocrinol Metab Research Article Duodenal mucosal resurfacing (DMR) is a new endoscopic ablation technique aimed at improving glycemia and metabolic control in patients with type 2 diabetes mellitus (T2DM). DMR appears to improve insulin resistance, which is the root cause of T2DM, but its mechanism of action is largely unknown. Bile acids function as intestinal signaling molecules in glucose and energy metabolism via the activation of farnesoid X receptor and secondary signaling [e.g., via fibroblast growth factor 19 (FGF19)], and are linked to metabolic health. We investigated the effect of DMR and glucagon-like peptide-1 (GLP-1) on postprandial bile acid responses in 16 patients with insulin-dependent T2DM, using mixed meal tests performed at the baseline and 6 mo after the DMR procedure. The combination treatment allowed discontinuation of insulin treatment in 11/16 (69%) of patients while improving glycemic and metabolic health. We found increased postprandial unconjugated bile acid responses (all P < 0.05), an overall increased secondary bile acid response (P = 0.036) and a higher 12α-hydroxylated:non-12α-hydroxylated ratio (P < 0.001). Total bile acid concentrations were unaffected by the intervention. Postprandial FGF19 and 7-α-hydroxy-4-cholesten-3-one (C4) concentrations decreased postintervention (both P < 0.01). Our study demonstrates that DMR with GLP-1 modulates the postprandial bile acid response. The alterations in postprandial bile acid responses may be the result of changes in the microbiome, ileal bile acid uptake and improved insulin sensitivity. Controlled studies are needed to elucidate the mechanism linking the combination treatment to metabolic health and bile acids. NEW & NOTEWORTHY Glycemic and metabolic improvements are seen in patients with type 2 diabetes after replacing their insulin therapy with DMR and GLP-1. These changes are accompanied by changes in postprandial bile acid concentrations: increased unconjugated and secondary bile acids. American Physiological Society 2022-02-01 2021-12-27 /pmc/articles/PMC8858668/ /pubmed/34957857 http://dx.doi.org/10.1152/ajpendo.00337.2021 Text en Copyright © 2022 The Authors https://creativecommons.org/licenses/by/4.0/Licensed under Creative Commons Attribution CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/) . Published by the American Physiological Society.
spellingShingle Research Article
Meiring, Suzanne
Meessen, Emma C. E.
van Baar, Annieke C. G.
Holleman, Frits
Nieuwdorp, Max
Olde Damink, Steven W.
Schaap, Frank G.
Vaz, Fred M.
Groen, Albert K.
Soeters, Maarten R.
Bergman, Jacques J. G. H. M.
Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes
title Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes
title_full Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes
title_fullStr Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes
title_full_unstemmed Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes
title_short Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes
title_sort duodenal mucosal resurfacing with a glp-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858668/
https://www.ncbi.nlm.nih.gov/pubmed/34957857
http://dx.doi.org/10.1152/ajpendo.00337.2021
work_keys_str_mv AT meiringsuzanne duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes
AT meessenemmace duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes
AT vanbaaranniekecg duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes
AT hollemanfrits duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes
AT nieuwdorpmax duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes
AT oldedaminkstevenw duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes
AT schaapfrankg duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes
AT vazfredm duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes
AT groenalbertk duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes
AT soetersmaartenr duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes
AT bergmanjacquesjghm duodenalmucosalresurfacingwithaglp1receptoragonistincreasespostprandialunconjugatedbileacidsinpatientswithinsulindependenttype2diabetes